Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Intangibles (2017 - 2023)

Aclaris Therapeutics has reported Intangibles over the past 7 years, most recently at $751000.0 for Q4 2023.

  • Quarterly results put Intangibles at $751000.0 for Q4 2023, down 89.23% from a year ago — trailing twelve months through Dec 2023 was $751000.0 (down 89.23% YoY), and the annual figure for FY2023 was $751000.0, down 89.23%.
  • Intangibles for Q4 2023 was $751000.0 at Aclaris Therapeutics, down from $7.4 million in the prior quarter.
  • Over the last five years, Intangibles for ACRS hit a ceiling of $73.8 million in Q2 2019 and a floor of $751000.0 in Q4 2023.
  • Median Intangibles over the past 5 years was $7.4 million (2019), compared with a mean of $13.4 million.
  • Biggest five-year swings in Intangibles: surged 909.37% in 2019 and later crashed 90.0% in 2020.
  • Aclaris Therapeutics' Intangibles stood at $7.2 million in 2019, then fell by 1.06% to $7.1 million in 2020, then dropped by 1.05% to $7.0 million in 2021, then dropped by 1.06% to $7.0 million in 2022, then tumbled by 89.23% to $751000.0 in 2023.
  • The last three reported values for Intangibles were $751000.0 (Q4 2023), $7.4 million (Q3 2023), and $7.4 million (Q2 2023) per Business Quant data.